Skip to main content
    W

    Werewolf Therapeutics Inc (HOWL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.99
    +0.01 (+1.07%)

    Market Cap: $47.64M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Werewolf Therapeutics Inc (HOWL) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Werewolf Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025, down 100.0% from the year before. That year, net income was -$60.82M, operating cash flow was -$60.29M and free cash flow was -$60.29M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$9.88M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $60.68M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0-100.0%N/AN/AN/A
    Dec 2024$1.89M-90.5%100.0%-3904.2%-3740.8%
    Dec 2023$19.94M+21.6%100.0%-203.1%-187.4%
    Dec 2022$16.40MN/A100.0%-341.8%-328.1%
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$0$1.89M$19.94M$16.40M$0$0$0
    Cost of revenue$0$0$0$0$0$0$463.00K
    Gross profit$0$1.89M$19.94M$16.40M$0$0-$463.00K
    Research and development$44.83M$56.43M$41.78M$53.76M$35.27M$16.64M$6.34M
    Operating income-$60.68M-$73.59M-$40.50M-$56.06M-$50.09M-$22.40M-$9.94M
    Net income-$60.82M-$70.52M-$37.37M-$53.81M-$49.98M-$15.04M-$10.99M
    EBITDA-$57.02M-$70.17M-$39.82M-$54.41M-$49.87M-$14.95M-$9.41M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$21.00M$0$0$0$0$0-$49.00K$0$1.14M$742.00K$1.50M
    Gross profit$0$21.00M$0-$400.00K$0$0$0-$967.00K$0$1.14M$742.00K$1.50M
    Operating income-$10.05M$7.16M-$13.27M-$9.42M-$15.73M-$17.54M-$17.99M-$20.35M-$17.12M-$18.96M-$17.16M-$12.96M
    Net income-$9.88M$3.67M-$13.53M-$8.38M-$16.37M-$17.98M-$18.09M-$20.40M-$16.67M-$17.25M-$16.19M-$12.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $28.24M by $28.81M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$69.40M$126.93M$174.83M$160.25M$179.25M$96.40M$21.68M
    Current assets$58.59M$113.07M$138.37M$140.20M$161.07M$92.91M$18.06M
    Cash and equivalents$57.05M$111.00M$134.34M$129.31M$157.53M$92.57M$17.90M
    Total liabilities$44.59M$53.54M$63.46M$37.91M$26.46M$7.18M$11.91M
    Short-term debt$28.24M$0$6.67M$0$1.07M$677.00K$595.00K
    Long-term debtN/A$26.09M$32.66M$0N/AN/AN/A
    Shareholder equity$24.80M$73.39M$111.37M$122.34M$152.79M-$51.86M$9.77M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$42.75M$24.16M$58.02M$69.40M$79.63M$92.57M$107.24M$126.93M$140.04M$153.70M$177.60M$174.83M
    Total liabilities$35.99M$7.86M$45.82M$44.59M$50.01M$51.10M$49.93M$53.54M$50.66M$49.69M$60.01M$63.46M
    Cash and equivalents$41.87M$21.99M$46.45M$57.05M$65.71M$77.60M$92.04M$111.00M$122.83M$135.30M$139.19M$134.34M
    Shareholder equity$6.76M$16.29M$12.20M$24.80M$29.61M$41.46M$57.31M$73.39M$89.38M$104.02M$117.59M$111.37M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$60.29M-$56.19M-$32.61M-$40.60M-$42.88M-$18.62M-$9.54M
    Capital expenditures$0$254.00K$769.00K$3.61M$498.00K$560.00K$266.00K
    Free cash flow-$60.29M-$56.44M-$33.38M-$44.21M-$43.37M-$19.18M-$9.81M
    Share repurchasesN/AN/AN/AN/A$2.38M$184.00KN/A
    Investing cash flow$0-$254.00K-$769.00K-$3.61M-$498.00K-$560.00K-$266.00K
    Financing cash flow$6.03M$13.08M$58.43M$15.91M$109.43M$93.86M$21.91M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$8.97M$6.63M-$10.60M-$11.02M-$15.16M-$15.16M-$18.95M-$14.25M-$12.46M-$14.18M-$15.30M-$4.58M
    Capital expendituresN/AN/A$0$0$0$0$0$123.00K$3.00K$17.00K$111.00K$198.00K
    Free cash flowN/AN/A-$10.60M-$11.02M-$15.16M-$15.16M-$18.95M-$14.38M-$12.46M-$14.19M-$15.41M-$4.78M
    Last 12 quarters

    Frequently Asked Questions About HOWL

    What is Werewolf Therapeutics' annual revenue?

    Werewolf Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    How fast is Werewolf Therapeutics' revenue growing?

    Revenue was down 100.0% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Werewolf Therapeutics profitable?

    No. Werewolf Therapeutics reported net income of -$60.82M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does HOWL generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$60.29M minus capital expenditures of $0 produced free cash flow of -$60.29M.

    How much debt does Werewolf Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $28.24M and cash and equivalents of $57.05M.